Exploration of the Clinical Treatment of Adenosquamous Carcinoma of the Pancreas

目的：对胰腺腺鳞癌的临床治疗进行初步探讨，以期提高临床认识和诊治水平，改善预后。方法：回顾性分析胰腺腺鳞癌的临床治疗8例，并结合文献资料进行讨论。结果：8例患者均经手术治疗，围手术期无死亡病例，术后3例联合化疗，平均生存期(7.4 ± 1.2)个月，中位生存期(7.3 ± 1.7)个月。结论：胰腺腺鳞癌恶性度高，预后差，R0手术切除是目前最有效的治疗方法，但联合脏器切除需注意损伤控制，术后联合放化疗等辅助治疗有助于生存期延长，但仍需临床进一步研究完善。从肿瘤学的角度出发开展多学科协作诊疗有可能成为提高胰腺腺鳞癌治疗效果的有效手段之一，免疫治疗也有可能为胰腺腺鳞癌的临床治疗带来新的思路。Objective: To study the clinical treatment of pancreatic adenosquamous carcinoma, in order to improve clinical recognition, diagnosis and treatment, and improve the prognosis. Methods: 8 cases of pancreatic adenosquamous carcinoma were analyzed retrospectively and discussed with the literature. Results: All of the 8 patients were treated by operation. There was no death in the perioperative period. The mean survival time was (7.4 ± 1.2) months and the median survival time was (7.3 ± 1.7) months. Conclusion: The malignant degree of pancreatic adenosquamous carcinoma is high and the prognosis is poor. R0 resection is the most effective treatment at present, but the combined organ resection needs to pay attention to damage control, postoperative adjuvant therapy such as radiotherapy and chemotherapy can help to prolong the survival period, but it still needs further clinical research and improvement. From the perspective of oncology, multi-disciplinary team may become one of the effective means to improve the therapeutic effect of pancreatic adenosquamous carcinoma. Immunotherapy may also bring new ideas for the clinical treatment of pancreatic adenosquamous carcinoma.